Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410049 | 0.91 | GAA (0.43) | CYP1A2CYP2C9CYP2C19HTTMGAM | |
| SCHEMBL8513088 | 0.86 | HDAC3 (0.40) | CYP1A2CYP2C9CYP2C19HTTMGAM | |
| SCHEMBL3825539 | 0.83 | L3MBTL1 (0.41) | CYP1A2CYP2C9CYP2C19HTTMGAM | |
| SCHEMBL460011 | 0.83 | MGAM (0.46) | CYP1A2MGAMGAASIMGAM2 | |
| SCHEMBL1194353 | 0.82 | GAA (0.50) | CYP1A2HTTMGAMGAASI | |
| SCHEMBL24834160 | 0.81 | ALDH1A1 (0.36) | GAAALDH1A1LMNATDP1HDAC3 | |
| SCHEMBL3823229 | 0.80 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19HTTMGAM | |
| SCHEMBL17425051 | 0.80 | CYP1A2 (0.39) | CYP1A2CYP2C9CYP2C19HTTMGAM | |
| SCHEMBL12877143 | 0.79 | GAA (0.48) | CYP1A2MGAMGAASIMGAM2 | |
| SCHEMBL3822316 | 0.79 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317009-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2008-01-08 | — | — | US | disclosed |
| US-7153854-B2 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1581535-A1 | PYRROLOPYRIDAZINE DERIVATIVES | Astellas Pharma Inc. (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050075342-A1 | Pyrrolopyridazine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-04-07 | — | — | US | disclosed |
| WO-2004063197-A1 | PYRROLOPYRIDAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075342-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | CYP1A2 367/4885CYP2C9 1113/4885CYP2C19 867/4885 |
| US-20060270678-A1 | Pyrrolopyridazine derivatives | PDE4A, PDE5A, PDE12 | CYP1A2 367/4885CYP2C9 1113/4885CYP2C19 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.